‘Cutting edge medical field’ blocked by regulation, looking for success in overseas
Kim Ji Seob | cloud50@ | 2017-08-08 11:41:23
High-tech medical companies, which have been limited from expanding their markets in Korea, are spreading their wings in overseas markets. They are getting more and more out of the country without using it properly in Korea despite Korean companies have advanced technology.
A study published in the International Journal of Nature in the Dawn of the Nineteenth (August 3) shows that human embryos are genetically modified to increase the risk of genetic disease. Dr. Kim Jin-soo, a research team leader of genomic proofreading research institute, presented a way to prevent genetic diseases such as hemophilia and Huntington`s disease through a joint research with Professor Shoukhrat Mitalipov of Oregon Health Science University (OHSU). However, in Korea, even if there is a source technology of `gene scissors` that can correct genes. It is not able to carry out such a study because of the restriction. The domestic bioethics law strictly limits human embryo research while the United States allows human embryo research for research purposes on genetic diseases that can affect future generations. In this study, domestic research team produced and provided gene scissors, which are the original technology used for experiments, and practical research was conducted by the American research team.
U-health care company Inseong Information recently signed a contract to supply 8,000 `High Care Hub`, its own branded remote medical device, through the `Home Telehealth` project of the US Veterans Administration until October. The project is a project to help US veterans manages their health at home. The US Veterans Affairs Department ordered a USD 1 billion (KRW 1.1 trillion) telemedicine project for five years. The telemedicine market, where doctors and patients do not face each other, is expected to grow from USD 18.1 billion in 2015 to USD 41.2 billion in 2021. In the United States, telemedicine has been activated since the 1990s, and next year, about 7 million people worldwide are expected to benefit from telemedicine. However, this is not possible in Korea as telemedicine between doctors and patients is illegal. The Ministry of Health and Welfare has submitted an amendment to the Medical Law that allows remote medical treatment between doctors and patients to the National Assembly, but it has not been passed on the contrary by the medical profession since 2010. Inseong Information said it plans to expand its operations overseas, including Latin America, including Brazil, and Europe in addition to exporting to the US public sector.
Bio-start up 3 billion was selected as a Korean national team winner in the 1776 Challenge Cup of global start-up competition last month. 1776 is a global incubator in the United States that provides initial funding for start-ups that can revolutionize the world`s problems. This year it will qualify in 75 cities around the world, and it is scheduled to run in New York in November. 3B is analyzing the genomes in saliva to develop a service that can diagnose 4,800 rare diseases at one time. It is a method to receive the result of the genetic analysis about 4 weeks after sending the spit from the homepage to the plastic container that came to the house.
3 billion is in the US testing service this year and will start commercialization next year. However, according to the Korea Bioethics Act, genetic testing is limited to 12 items such as body mass index, caffeine metabolism, blood pressure, blood sugar, skin aging, pigmentation, and hair thickness. In July of last year, as household genetic testing (DTC) became available, companies such as Terajin Dexex and DENEI Link have launched a series of related products, but the market is not so great because they can receive genetic tests only in limited areas. An industry expert said, "Although competition in the advanced industrial market for the 4th industry in the world is intensifying, the domestic market is blocked by various regulations." If it is difficult to build a reference in Korea, the industry development will be slow.”
By Kim Ji Seob cloud50@
[ copyright ⓒ The Digitaltimes ]
A study published in the International Journal of Nature in the Dawn of the Nineteenth (August 3) shows that human embryos are genetically modified to increase the risk of genetic disease. Dr. Kim Jin-soo, a research team leader of genomic proofreading research institute, presented a way to prevent genetic diseases such as hemophilia and Huntington`s disease through a joint research with Professor Shoukhrat Mitalipov of Oregon Health Science University (OHSU). However, in Korea, even if there is a source technology of `gene scissors` that can correct genes. It is not able to carry out such a study because of the restriction. The domestic bioethics law strictly limits human embryo research while the United States allows human embryo research for research purposes on genetic diseases that can affect future generations. In this study, domestic research team produced and provided gene scissors, which are the original technology used for experiments, and practical research was conducted by the American research team.
U-health care company Inseong Information recently signed a contract to supply 8,000 `High Care Hub`, its own branded remote medical device, through the `Home Telehealth` project of the US Veterans Administration until October. The project is a project to help US veterans manages their health at home. The US Veterans Affairs Department ordered a USD 1 billion (KRW 1.1 trillion) telemedicine project for five years. The telemedicine market, where doctors and patients do not face each other, is expected to grow from USD 18.1 billion in 2015 to USD 41.2 billion in 2021. In the United States, telemedicine has been activated since the 1990s, and next year, about 7 million people worldwide are expected to benefit from telemedicine. However, this is not possible in Korea as telemedicine between doctors and patients is illegal. The Ministry of Health and Welfare has submitted an amendment to the Medical Law that allows remote medical treatment between doctors and patients to the National Assembly, but it has not been passed on the contrary by the medical profession since 2010. Inseong Information said it plans to expand its operations overseas, including Latin America, including Brazil, and Europe in addition to exporting to the US public sector.
Bio-start up 3 billion was selected as a Korean national team winner in the 1776 Challenge Cup of global start-up competition last month. 1776 is a global incubator in the United States that provides initial funding for start-ups that can revolutionize the world`s problems. This year it will qualify in 75 cities around the world, and it is scheduled to run in New York in November. 3B is analyzing the genomes in saliva to develop a service that can diagnose 4,800 rare diseases at one time. It is a method to receive the result of the genetic analysis about 4 weeks after sending the spit from the homepage to the plastic container that came to the house.
3 billion is in the US testing service this year and will start commercialization next year. However, according to the Korea Bioethics Act, genetic testing is limited to 12 items such as body mass index, caffeine metabolism, blood pressure, blood sugar, skin aging, pigmentation, and hair thickness. In July of last year, as household genetic testing (DTC) became available, companies such as Terajin Dexex and DENEI Link have launched a series of related products, but the market is not so great because they can receive genetic tests only in limited areas. An industry expert said, "Although competition in the advanced industrial market for the 4th industry in the world is intensifying, the domestic market is blocked by various regulations." If it is difficult to build a reference in Korea, the industry development will be slow.”
By Kim Ji Seob cloud50@